Nektar Therapeutics
Index- P/E- EPS (ttm)-2.67 Insider Own0.90% Shs Outstand185.85M Perf Week-13.96%
Market Cap636.34M Forward P/E- EPS next Y-0.98 Insider Trans-7.20% Shs Float184.15M Perf Month-28.18%
Income-491.30M PEG- EPS next Q-0.91 Inst Own95.50% Short Float9.96% Perf Quarter-65.34%
Sales103.10M P/S6.17 EPS this Y-14.80% Inst Trans1.30% Short Ratio4.34 Perf Half Y-70.57%
Book/sh3.27 P/B1.04 EPS next Y50.80% ROA-41.00% Target Price5.83 Perf Year-80.71%
Cash/sh3.55 P/C0.95 EPS next 5Y-7.30% ROE-65.60% 52W Range3.52 - 19.37 Perf YTD-74.91%
Dividend- P/FCF- EPS past 5Y-21.00% ROI-65.70% 52W High-82.50% Beta1.33
Dividend %- Quick Ratio6.80 Sales past 5Y-9.20% Gross Margin76.30% 52W Low-3.69% ATR0.38
Employees740 Current Ratio7.00 Sales Q/Q5.10% Oper. Margin- RSI (14)32.00 Volatility8.10% 8.70%
OptionableYes Debt/Eq0.00 EPS Q/Q28.30% Profit Margin- Rel Volume0.76 Prev Close3.57
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume4.22M Price3.39
Recom3.00 SMA20-16.56% SMA50-30.19% SMA200-70.55% Volume3,209,996 Change-5.04%
Apr-18-22Downgrade Goldman Neutral → Sell $3
Mar-15-22Downgrade Mizuho Buy → Neutral $35 → $8
Mar-15-22Downgrade Cowen Outperform → Market Perform
Mar-14-22Downgrade William Blair Outperform → Mkt Perform
Mar-14-22Downgrade Stifel Buy → Hold $24 → $5
Mar-14-22Downgrade BTIG Research Buy → Neutral
Mar-14-22Downgrade BofA Securities Neutral → Underperform $18 → $6
Mar-09-22Upgrade Oppenheimer Perform → Outperform $21
Nov-08-21Upgrade The Benchmark Company Hold → Buy $20
Sep-10-21Initiated BofA Securities Neutral $18
Jun-28-21Upgrade Stifel Hold → Buy $22 → $24
May-18-21Resumed Goldman Neutral $24
Feb-22-21Downgrade The Benchmark Company Buy → Hold
Jan-06-21Initiated Stifel Hold $18
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
May-16-22 02:09PM  
May-06-22 10:07AM  
May-05-22 05:55PM  
May-04-22 08:15AM  
Apr-28-22 03:02PM  
Apr-27-22 12:00PM  
Apr-26-22 09:19AM  
Apr-25-22 06:00PM  
Apr-22-22 08:30AM  
Apr-20-22 12:54PM  
Apr-18-22 05:25PM  
Apr-14-22 04:42PM  
Apr-05-22 05:50AM  
Mar-30-22 11:30AM  
Mar-16-22 12:32PM  
Mar-15-22 10:38AM  
Mar-14-22 05:43PM  
Mar-04-22 09:22AM  
Mar-01-22 10:43AM  
Feb-28-22 05:35PM  
Feb-17-22 06:00PM  
Feb-08-22 09:38AM  
Feb-03-22 01:38PM  
Jan-31-22 03:35PM  
Jan-21-22 01:38PM  
Jan-20-22 09:38PM  
Jan-19-22 01:38PM  
Jan-05-22 09:00AM  
Jan-03-22 09:38PM  
Dec-31-21 08:56AM  
Dec-15-21 09:10AM  
Dec-14-21 11:31AM  
Dec-13-21 03:59PM  
Dec-11-21 12:38AM  
Dec-03-21 07:51PM  
Nov-30-21 08:00AM  
Nov-19-21 11:52AM  
Nov-15-21 08:30AM  
Nov-12-21 07:00AM  
Nov-09-21 08:15AM  
Nov-05-21 04:11PM  
Nov-04-21 10:32PM  
Oct-26-21 06:00PM  
Oct-25-21 04:01PM  
Sep-22-21 11:09AM  
Sep-21-21 11:02AM  
Sep-13-21 11:47AM  
Sep-02-21 12:03PM  
Aug-06-21 12:31PM  
Aug-05-21 09:31PM  
Jul-29-21 03:05PM  
Jul-27-21 06:00PM  
Jul-26-21 05:09PM  
Jul-19-21 09:00AM  
Jun-07-21 08:30AM  
Jun-04-21 10:46AM  
May-27-21 06:36AM  
May-20-21 11:00AM  
May-18-21 08:00AM  
May-10-21 03:09AM  
May-07-21 03:30AM  
May-06-21 05:45PM  
Apr-29-21 12:34PM  
Apr-27-21 06:00PM  
Mar-27-21 11:31AM  
Feb-26-21 09:09AM  
Feb-25-21 05:10PM  
Feb-18-21 05:30PM  
Feb-17-21 04:19PM  
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zalevsky JonathanChief R&D OfficerMay 16Sale3.9521,67385,608276,399May 17 09:40 PM
Wilson Mark AndrewSVP & General CounselMay 16Sale3.953,13612,387117,939May 17 09:38 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale3.955,84123,072170,427May 17 09:36 PM
ROBIN HOWARD WPresident & CEOMay 16Sale3.9536,529144,290620,941May 17 09:35 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerMay 16Sale3.954,59218,138223,210May 17 09:33 PM
Labrucherie Gil MSVP, COO & CFOMay 16Sale3.9517,44868,920312,905May 17 09:32 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale10.9510,912119,486274,122Feb 18 06:20 PM
Wilson Mark AndrewSVP & General CounselFeb 16Sale10.953,66140,088121,075Feb 18 06:18 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale10.952,36325,875165,318Feb 18 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale10.9512,480136,656589,020Feb 18 06:16 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerFeb 16Sale10.954,85253,129227,802Feb 18 06:15 PM
Labrucherie Gil MSVP, COO & CFOFeb 16Sale10.957,57982,990301,603Feb 18 06:14 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale12.693,00038,070256,682Nov 18 06:06 PM
Labrucherie Gil MSVP, COO & CFONov 16Sale13.1621,149278,321259,682Nov 18 06:06 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale13.1620,869274,636232,084Nov 17 06:11 PM
Wilson Mark AndrewSVP & General CounselNov 16Sale13.166,56486,38286,436Nov 17 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale13.166,74188,712145,981Nov 17 06:08 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerNov 16Sale13.166,06179,763194,854Nov 17 06:06 PM
ROBIN HOWARD WPresident & CEONov 16Sale13.1642,773562,893475,450Nov 17 06:07 PM
GREER R SCOTTDirectorNov 09Option Exercise12.8012,500160,000293,374Nov 09 05:05 PM
Curet MyriamDirectorSep 22Sale17.783,66565,16425,775Sep 24 06:14 PM
CHESS ROBERTDirectorSep 22Sale17.944,60082,524279,873Sep 24 06:13 PM
Ajer Jeffrey RobertDirectorSep 22Sale17.783,66565,16432,510Sep 24 06:12 PM
WHITFIELD ROY ADirectorSep 16Option Exercise13.8040,000552,000225,850Sep 17 06:44 PM
CHESS ROBERTDirectorSep 09Option Exercise13.8010,279141,850284,552Sep 10 06:03 PM
CHESS ROBERTDirectorSep 09Sale16.0210,279164,670274,273Sep 10 06:03 PM
CHESS ROBERTDirectorSep 08Option Exercise13.808,000110,400282,273Sep 10 06:03 PM
CHESS ROBERTDirectorSep 08Sale16.008,000128,000274,273Sep 10 06:03 PM
GREER R SCOTTDirectorAug 31Option Exercise12.7045,000571,500270,674Aug 31 06:26 PM
Labrucherie Gil MSVP, COO & CFOAug 17Sale13.563,00040,680240,231Aug 18 06:58 PM
Zalevsky JonathanChief R&D OfficerAug 16Sale13.837,662105,965212,803Aug 18 07:04 PM
Wilson Mark AndrewSVP & General CounselAug 16Sale13.831,91026,41572,900Aug 18 07:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale13.8313,339184,478137,822Aug 18 07:00 PM
ROBIN HOWARD WPresident & CEOAug 16Sale13.8311,515159,252424,123Aug 18 07:01 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerAug 16Sale13.836,19285,635200,915Aug 18 06:59 PM
Labrucherie Gil MSVP, COO & CFOAug 16Sale13.837,867108,801243,231Aug 18 06:58 PM
CHESS ROBERTDirectorJul 22Option Exercise13.80911,256280,664Jul 22 07:13 PM
CHESS ROBERTDirectorJul 22Sale16.80911,529280,573Jul 22 07:13 PM
CHESS ROBERTDirectorJul 21Option Exercise13.803,52448,631284,097Jul 22 07:13 PM
CHESS ROBERTDirectorJul 21Sale16.813,52459,238280,573Jul 22 07:13 PM
CHESS ROBERTDirectorJul 20Option Exercise13.802,10629,063282,679Jul 22 07:13 PM
CHESS ROBERTDirectorJul 20Sale16.802,10635,381280,573Jul 22 07:13 PM